Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy

Xuan, Lihui; Bai, Chenjun; Ju, Zhao; Luo, Jinhua; Guan, Hua; Zhou, Ping-Kun; Huang, Ruixue

doi:10.1016/j.cytogfr.2023.11.003

Cited by 3 publications

(1 citation statement)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of radiation therapy in modulating the immune system, thereby creating an environment conducive to anti-tumor immunity, is increasingly recognized [ 13 , 14 ]. Radiation therapy is noted for its diverse immunomodulatory effects, including enhanced antigen presentation, chemokine secretion, effector T-cell recruitment to the tumor site, and promoting immunogenic cell death driven by lymphocytes [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis

Cui,

Li,

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background The recent usage of immunotherapy combined with chemoradiotherapy has improved survival in advanced non-small cell lung cancer (NSCLC) patients. However, determining the most effective therapy combination remains a topic of debate. Research suggests immune checkpoint inhibitors (ICIs) post-chemoradiotherapy enhance survival, but the impact of concurrent ICIs during chemoradiotherapy on rapid disease progression is unclear. This meta-analysis aims to assess the effectiveness and safety of concurrent ICIs with radiotherapy or chemoradiotherapy in advanced non-small cell lung cancer. Methods We searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant studies, extracting data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs). Results The analysis included ten studies with 490 participants. Stage III NSCLC ORR was 81.8%, while Stage IV ORR was 39.9%. One-year PFS and OS for Stage III were 68.2% and 82.6%, compared to 27.9% and 72.2% for Stage IV. Common adverse events included anemia (46.6%), nausea (47.6%), rash (36.4%), and radiation pneumonitis (36.3%). Conclusions Our meta-analysis shows concurrent ICIs with chemoradiotherapy are effective and safe in advanced NSCLC, particularly in stage III patients at risk of progression before starting ICIs after chemoradiotherapy. The findings support further phase III trials. The review protocol was registered on PROSPERO (CRD42023493685) and is detailed on the NIHR HTA programme website.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis

Cui,

Li,

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

Biomineralization strategy: from material manufacturing to biological regulation

Qin,

Zheng,

Wang

et al. 2024

Giant

View full text Add to dashboard Cite

A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects

Amilo,

Izuchukwu,

Sadri

et al. 2024

Sci Rep

View full text Add to dashboard Cite

This research presents a novel approach to address the complexities of heterogeneous lung cancer dynamics through the development of a Fractional-Order Model. Focusing on the optimization of combination therapy, the model integrates immunotherapy and targeted therapy with the specific aim of minimizing side effects. Notably, our approach incorporates a clever fusion of Proportional-Integral-Derivative (PID) feedback controls alongside the optimization process. Unlike previous studies, our model incorporates essential equations accounting for the interaction between regular and mutated cancer cells, delineates the dynamics between immune cells and mutated cancer cells, enhances immune cell cytotoxic activity, and elucidates the influence of genetic mutations on the spread of cancer cells. This refined model offers a comprehensive understanding of lung cancer progression, providing a valuable tool for the development of personalized and effective treatment strategies. the findings underscore the potential of the optimized treatment strategy in achieving key therapeutic goals, including primary tumor control, metastasis limitation, immune response enhancement, and controlled genetic mutations. The dynamic and adaptive nature of the treatment approach, coupled with economic considerations and memory effects, positions the research at the forefront of advancing precision and personalized cancer therapeutics.

show abstract

Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy

Cited by 3 publications

References 146 publications

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis

Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis

Biomineralization strategy: from material manufacturing to biological regulation

A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects

Contact Info

Product

Resources

About